Octave® Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate  Biomarker Test for Parkinson’s Disease. Learn More


From subjectivity to objective biological measurements


The first and only multivariate biomarker blood test


that provides accurate measurement of MS disease activity.


No data at the biological level

With current tools, changes in multiple sclerosis disease activity are often invisible—until it’s too late.


Real-time insight
for faster, smarter intervention

We’re changing that.
Introducing our first-in-class disease activity blood test, which provides real-time assessment of the underlying biology, pathways, mechanisms, and cell types involved in a patient’s MS.


Dynamic, multianalyte

Our multi-protein assay is a dynamic measure of immune modulation, inflammation, myelin biology, and neuroaxonal integrity validated through an extensive multiple sclerosis research and development process and clinical study.


Address real, debilitating issues in MS care

Finally, a solution to quantitatively measure subclinical multiple sclerosis disease activity and detect relapses that can be used to identify suboptimal responses to current interventions. This is only the beginning—we’re at work
on other serum-based tests to bring additional insights to light.

Key Applications

The Octave disease activity test helps you
Support DMT selection based on disease phenotype

Conduct routine surveillance

Evaluate stability vs. slow decline

Monitor new MS symptoms - evaluation for relapse

Monitor patients who have been discontinued from DMTs

The Octave Bioscience Clinical Laboratory is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing and is a College of American Pathology (CAP) Accredited Laboratory.

CLIA ID #05D2168340


See the Science

Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

Study Published in Clinical Immunology

View Article

Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis

Research Presented at MSMilan 2023 - October 11-13

Download PDF
View All Publications